Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign up Log in
What is This Site Help Center Crisis
Powered By

Top 5 search results for "Idhifa" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
How Is AML Different From CML Blast Crisis?
... These drugs, which are typically used in people who can’t tolerate chemotherapy or are older, include: Enasidenib (Idhifa) Midostaurin (Rydapt) Venetoclax (Venclexta) Ivosidenib (Tibsovo) Gilteritinib (Xospata) Treatments for CML Blast CrisisThe BCR-ABL gene encodes a protein known as a tyrosine kinase. ...
How Is AML Different From CML Blast Crisis?
... These drugs, which are typically used in people who can’t tolerate chemotherapy or are older, include: Enasidenib (Idhifa) Midostaurin (Rydapt) Venetoclax (Venclexta) Ivosidenib (Tibsovo) Gilteritinib (Xospata) Treatments for CML Blast CrisisThe BCR-ABL gene encodes a protein known as a tyrosine kinase. ...
The Benefits of Targeted Therapy for Leukemia
... Ivosidenib (Tibsovo) can help treat people with IDH1 mutations, while enasidenib (Idhifa) is a treatment option for people with IDH2 mutations. Certain people with AML may also be able to take glasdegib (Daurismo). ...
The Benefits of Targeted Therapy for Leukemia
... Ivosidenib (Tibsovo) can help treat people with IDH1 mutations, while enasidenib (Idhifa) is a treatment option for people with IDH2 mutations. Certain people with AML may also be able to take glasdegib (Daurismo). ...
AML vs. CML: How Do These Leukemia Types and Their Treatments Differ?
... People with a mutation in the IDH2 gene can use enasidenib (Idhifa). These drugs may be used alone or with chemotherapy, particularly in older adults or those who cannot tolerate intensive chemotherapy.Because almost all CML cells have the same mutation causing abnormal tyrosine kinase activity, certain targeted therapies inhibit this protein. ...
AML vs. CML: How Do These Leukemia Types and Their Treatments Differ?
... People with a mutation in the IDH2 gene can use enasidenib (Idhifa). These drugs may be used alone or with chemotherapy, particularly in older adults or those who cannot tolerate intensive chemotherapy.Because almost all CML cells have the same mutation causing abnormal tyrosine kinase activity, certain targeted therapies inhibit this protein. ...
8 Leukemia Treatment Options You Should Know
... IDH inhibitors include: Enasidenib (Idhifa) Ivosidenib (Tibsovo) Menin InhibitorsMenin inhibitors, like revumenib (Revuforj), are a newer class of targeted therapies specifically designed for cases of acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation. ...
8 Leukemia Treatment Options You Should Know
... IDH inhibitors include: Enasidenib (Idhifa) Ivosidenib (Tibsovo) Menin InhibitorsMenin inhibitors, like revumenib (Revuforj), are a newer class of targeted therapies specifically designed for cases of acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation. ...
Acute Lymphoblastic Leukemia (ALL) vs. Acute Myeloid Leukemia (AML): Understanding the Difference
... People with relapsed or refractory (resistant to treatment) AML and a mutation in the IDH2 gene may be able to use Idhifa (enasidenib). People with relapsed or refractory AML with an IDH1 gene mutation can be treated with Tibsovo (ivosidenib). ...
Acute Lymphoblastic Leukemia (ALL) vs. Acute Myeloid Leukemia (AML): Understanding the Difference
... People with relapsed or refractory (resistant to treatment) AML and a mutation in the IDH2 gene may be able to use Idhifa (enasidenib). People with relapsed or refractory AML with an IDH1 gene mutation can be treated with Tibsovo (ivosidenib). ...